Literature DB >> 24187445

Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Daniel E Freedberg1, Julian A Abrams.   

Abstract

Once a nosocomial disease, Clostridium difficile infection (CDI) now appears frequently in the community in the absence of exposure to antibiotics. Prior studies have shown that patients with community-acquired CDI are younger, more likely to be female, and have fewer comorbidities compared to patients with hospital-associated CDI. Because most studies of CDI are hospital-based, comparatively little is known about community-acquired CDI. The recent study by Chitnis has received widespread attention because it used active surveillance to capture all cases of community-acquired CDI within a large population and assessed key risk factors. The authors found that low-level healthcare exposure and proton pump inhibitor use were common among those with non-antibiotics associated, community-acquired CDI. In this commentary, we discuss the changing epidemiology of community-acquired CDI and the evidence basis for the controversial association between proton pump inhibitors and community-acquired CDI.

Entities:  

Keywords:  Anti-bacterial agents; Clostridium difficile; Disease outbreaks; Epidemics; Pharmacoepidemiology; Proton pump inhibitors; Pseudomembranous enterocolitis; Public health

Mesh:

Year:  2013        PMID: 24187445      PMCID: PMC3812469          DOI: 10.3748/wjg.v19.i40.6710

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.

Authors:  Chun Shing Kwok; Aaron Kobina Arthur; Chukwudubem Ifeanyichukwu Anibueze; Sonal Singh; Rodrigo Cavallazzi; Yoon Kong Loke
Journal:  Am J Gastroenterol       Date:  2012-04-24       Impact factor: 10.864

2.  Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.

Authors:  Sailajah Janarthanan; Ivo Ditah; Douglas G Adler; Murray N Ehrinpreis
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

3.  Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora.

Authors:  A Bühling; D Radun; W A Müller; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

4.  Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control.

Authors:  Charis A Marwick; Ning Yu; Michael C Lockhart; Christopher C McGuigan; Camilla Wiuff; Peter G Davey; Peter T Donnan
Journal:  J Antimicrob Chemother       Date:  2013-07-03       Impact factor: 5.790

5.  Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost.

Authors:  M W Climo; D S Israel; E S Wong; D Williams; P Coudron; S M Markowitz
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

6.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

Authors:  J G Bartlett; T W Chang; M Gurwith; S L Gorbach; A B Onderdonk
Journal:  N Engl J Med       Date:  1978-03-09       Impact factor: 91.245

7.  Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin.

Authors:  G D Rifkin; F R Fekety; J Silva
Journal:  Lancet       Date:  1977-11-26       Impact factor: 79.321

8.  Who is using chronic acid suppression therapy and why?

Authors:  Brian C Jacobson; Timothy G Ferris; Tara L Shea; Emmanuel M Mahlis; Thomas H Lee; Timothy C Wang
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

9.  Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.

Authors:  Amit S Chitnis; Stacy M Holzbauer; Ruth M Belflower; Lisa G Winston; Wendy M Bamberg; Carol Lyons; Monica M Farley; Ghinwa K Dumyati; Lucy E Wilson; Zintars G Beldavs; John R Dunn; L Hannah Gould; Duncan R MacCannell; Dale N Gerding; L Clifford McDonald; Fernanda C Lessa
Journal:  JAMA Intern Med       Date:  2013-07-22       Impact factor: 21.873

10.  Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data.

Authors:  Sinead Brophy; Kerina H Jones; Muhammad A Rahman; Shang-Ming Zhou; Ann John; Mark D Atkinson; Nick Francis; Ronan A Lyons; Frank Dunstan
Journal:  Am J Gastroenterol       Date:  2013-04-16       Impact factor: 10.864

View more
  3 in total

1.  Flooding and Clostridium difficile Infection: A Case-Crossover Analysis.

Authors:  Cynthia J Lin; Timothy J Wade; Elizabeth D Hilborn
Journal:  Int J Environ Res Public Health       Date:  2015-06-17       Impact factor: 3.390

Review 2.  Community-acquired Clostridium difficile infection: an increasing public health threat.

Authors:  Arjun Gupta; Sahil Khanna
Journal:  Infect Drug Resist       Date:  2014-03-17       Impact factor: 4.003

Review 3.  Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.

Authors:  Lauren E Bloomfield; Thomas V Riley
Journal:  Infect Dis Ther       Date:  2016-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.